Vancouver, Canada — Anavex Life Sciences Corp. (“Anavex”) announced on July 9 that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease currently in human clinical trials, will be presented in a poster session at the 2012 Alzheimer’s Association International Conference (AAIC) in Vancouver, BC, Canada.

The ANAVEX 2-73 poster will be presented by Tangui Maurice, PhD, CNRS Research Director, Team II Endogenous Neuroprotection in Neurodegenerative Diseases INSERM, University of Montpellier. The presentation will be held on Monday, July 16 from 1 PM- 3:30 PM. The title of the presentation will be: ”Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer’s disease: Analyses of administration schedules and combination studies with donepezil and memantine.”

AAIC 2012 takes place Saturday, July 14 to Thursday, July 19, 2012 in Vancouver. It is the world’s premiere forum for reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer’s disease and related disorders. The conference website boasts that AAIC 2012 will “join the world’s leading dementia scientists to share the latest thoughts and theories in the field – and spark new ideas along the way.” Additional information about the conference is available at http://www.alz.org/aaic/.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug candidates. Anavex utilizes its proprietary SIGMACEPTOR Platform to develop drug candidates targeting specific clinical indications. Lead compound ANAVEX 2-73, developed to treat Alzheimer’s through disease modification, is in human clinical trials.

A Phase 1 single ascending dose study of ANAVEX 2-73 was successfully completed in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties, and that it is well tolerated in doses up to 55mg. The company is preparing to embark on a multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex is a publicly traded corporation quoted as AVXL.

Image Courtesy of   Argonne National Laboratory

The article New Alzheimer’s Drug Shows Promise appeared first on The Toonari Post - News, Powered by the People!.

After a two-day meeting of government leaders and private sector experts that focused on the proposed framework of an historic national plan to defeat Alzheimer’s disease, Eric J. Hall, founding president and CEO of the Alzheimer’s Foundation of America (AFA) and a member of the Advisory Council on Alzheimer’s Research, Care and Services established by the National Alzheimer’s Project Act (NAPA),on January 19 released this statement:

“Our nation is placing an intense and unprecedented focus on Alzheimer’s disease right now, giving hope to Americans that the bold recommendations and thoughtful discussion that emerged during his meeting of the Advisory Council and ongoing will result in a powerful plan that turns the tide of the disease.

“In the year since NAPA was passed by Congress and signed by President Obama, the Alzheimer’s Foundation of America has consistently sought input from family caregivers, clinicians, researchers, healthcare professionals, policymakers and the general public about their personal and professional experiences with Alzheimer’s disease, their recommendations for change and their hopes that the NAPA process goes beyond a ‘check the box exercise.’

Their voices formed the basis of AFA’s report ‘No Time to Waste,’ which provides hard-hitting recommendations that align with the draft plan being discussed by the Advisory Council. “Never before has our nation been poised like this to pursue and achieve what Americans facing this devastating brain disorder demand and deserve.

We are at a pivotal juncture to alter the current course of Alzheimer’s disease, and we must act aggressively yet realistically in order to carry the momentum forward.

“Since fiscal concerns and the growth of the Alzheimer’s population cannot go unnoticed, it is critical that we design this plan with incremental, fundable and attainable goals, which include substantially increasing our scientific knowledge surrounding the disease; preventing, delaying and slowing progression of symptoms; researching and implementing best practices of care; providing much-needed support services for families; and ultimately obtaining the cure we are all waiting for.

“There’s no doubt that we have no time to waste, but it will be vital to engage Congress and sustain their commitment in order to achieve a national plan to defeat Alzheimer’s disease and help countless families now and in the future. Much work lies ahead, but I am confident that we are on the right path toward the resolution of this crisis.”

The Alzheimer’s Foundation of America (AFA) released its “No Time to Waste” report in October 2011 in response to the mandate by NAPA for federal officials to develop an integrated national plan to defeat Alzheimer’s disease.  AFA’s report urges wide-scale public awareness campaigns, including messaging to drive earlier detection and to “shift the focus from fear to acceptance of the disease.”

Other calls for action include: a substantial investment in research toward the prevention, treatment, care and cure of Alzheimer’s disease; additional dementia training and reimbursement for primary care clinicians; and greater training and support for family caregivers of all demographics, including teenagers and ethnic populations, across the continuum of care.

At the Advisory Council meeting this week, Hall further recommended family-friendly workplace policies; tax breaks for expenses related to care giving of loved ones with Alzheimer’ disease; and Medicare-provided support services, such as respite care, that can greatly benefit both individuals with the disease and the health and well-being of family caregivers.   Image Courtesy of   https://www.facebook.com/AlzheimersFoundationofAmerica

The article Forward Movement for National Alzheimer’s Plan appeared first on The Toonari Post - News, Powered by the People!.